Literature DB >> 28151386

Clinical experience reversing factor Xa inhibitors with four-factor prothrombin complex concentrate in a community hospital.

Katie B Tellor1, Naomi S Barasch2, Brian M Lee2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28151386      PMCID： PMC6034772          DOI： 10.2450/2017.0219-16

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  9 in total

1.  Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.

Authors:  S Kaatz; D Ahmad; A C Spyropoulos; S Schulman
Journal:  J Thromb Haemost       Date:  2015-11       Impact factor: 5.824

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.

Authors:  Hamim Zahir; Karen S Brown; Alexander G Vandell; Madhuri Desai; Jen-Fue Maa; Victor Dishy; Barbara Lomeli; Annette Feussner; Wenqin Feng; Ling He; Michael A Grosso; Hans J Lanz; Elliott M Antman
Journal:  Circulation       Date:  2014-11-17       Impact factor: 29.690

4.  The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban: A Multicenter Evaluation.

Authors:  Lesley Pahs; Craig Beavers; Patricia Schuler
Journal:  Crit Pathw Cardiol       Date:  2015-06

Review 5.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.

Authors:  Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

6.  Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Authors:  Elise S Eerenberg; Pieter W Kamphuisen; Meertien K Sijpkens; Joost C Meijers; Harry R Buller; Marcel Levi
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

Review 7.  Advanced trauma life support, 8th edition, the evidence for change.

Authors:  John B Kortbeek; Saud A Al Turki; Jameel Ali; Jill A Antoine; Bertil Bouillon; Karen Brasel; Fred Brenneman; Peter R Brink; Karim Brohi; David Burris; Reginald A Burton; Will Chapleau; Wiliam Cioffi; Francisco De Salles Collet e Silva; Art Cooper; Jaime A Cortes; Vagn Eskesen; John Fildes; Subash Gautam; Russell L Gruen; Ron Gross; K S Hansen; Walter Henny; Michael J Hollands; Richard C Hunt; Jose M Jover Navalon; Christoph R Kaufmann; Peggy Knudson; Amy Koestner; Roman Kosir; Claus Falck Larsen; West Livaudais; Fred Luchette; Patrizio Mao; John H McVicker; Jay Wayne Meredith; Charles Mock; Newton Djin Mori; Charles Morrow; Steven N Parks; Pedro Moniz Pereira; Renato Sergio Pogetti; Jesper Ravn; Peter Rhee; Jeffrey P Salomone; Inger B Schipper; Patrick Schoettker; Martin A Schreiber; R Stephen Smith; Lars Bo Svendsen; Wa'el Taha; Mary van Wijngaarden-Stephens; Endre Varga; Eric J Voiglio; Daryl Williams; Robert J Winchell; Robert Winter
Journal:  J Trauma       Date:  2008-06

8.  Prothrombin complex concentrate for the management of severe traumatic bleeding in a patient anticoagulated with apixaban.

Authors:  R Durie; M Kohute; C Fernandez; M Knight
Journal:  J Clin Pharm Ther       Date:  2015-12-18       Impact factor: 2.512

9.  Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.

Authors:  Ramesh Grandhi; W Christopher Newman; Xiaoran Zhang; Gillian Harrison; Colleen Moran; David O Okonkwo; Andrew F Ducruet
Journal:  World Neurosurg       Date:  2015-09-01       Impact factor: 2.104
  9 in total
  4 in total

Review 1.  The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review.

Authors:  Maureane Hoffman; Joshua N Goldstein; Jerrold H Levy
Journal:  Int J Emerg Med       Date:  2018-12-03

Review 2.  A review of guidelines on anticoagulation reversal across different clinical scenarios - Is there a general consensus?

Authors:  Truman J Milling; Charles V Pollack
Journal:  Am J Emerg Med       Date:  2020-05-28       Impact factor: 4.093

3.  Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding.

Authors:  Victoria M Stevens; Toby C Trujillo; Tyree H Kiser; Robert MacLaren; Paul M Reynolds; Scott W Mueller
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

Review 4.  Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.

Authors:  Rami A Al-Horani
Journal:  Am J Cardiovasc Drugs       Date:  2020-12       Impact factor: 3.283
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.